Variations in the tumor microenvironment (TME) play crucial roles in tumor progression. Complex metabolic crosstalk, involving nutrient availability, physicochemical transformations, and intercellular interactions, between the immune system and TEM, directly or indirectly contribute to tumor immune escape. Over the recent decades, immune-based interventions, such as cellular antigenic epitope detection for tumor diagnosis, exogenous immune effectors for tumor therapy, and immunogenic tumor vaccine for tumor prevention, have shown great potential in clinical applications. However, the lack of a comprehensive understanding of the TME as it relates to immune treatment strategies administration could bring about unobjective effects on patients; for example, off-target effects, cytokine release syndrome, or organic adverse events. A further understanding of immunometabolic interplay mechanisms will facilitate tumor treatment, which is still of limited knowledge. Thus, explorations on immunometabolic interplay and TEM turbulence, from bench to bedside, will help clinicians have a better grasp on human disease treatment.
The issue of “metabonomics and cancer immunotherapy: interplay and clinical implications” aims at improving our understanding of immuno-metabolic variations in TME and assisting optimized strategy formulation in clinical practice. It will also thoroughly describe the interplay between metabolic networks, the body’s immunity, and TME. Based on advances in our understanding of the mechanism of immuno-metabolism, strategies for pan-cancer diagnosis, therapy, and prevention can be better investigated, which will improve solutions to current pan-cancer research impediments.
We welcome original research, review, mini-review, systematic review, and perspective articles on subtopics including, but not limited to:
1. Immunometabolic pan-cancer interplay.
2. Metabonomic analysis of tumor microenvironments
3. Metabonomic-related mechanisms for immune cell function and dysfunction, and tumor microenvironment turbulence
4. Optimized organoid models for tumor therapeutic research
5. Interdisciplinary studies on immunometabolic interplay
6. Immuno-metabonomic variations and their clinical pan-cancer implications
7. Immuno-metabolism targeted strategies for pan-cancer diagnosis, therapy, and prevention
8. Obstacles and solutions in immune-metabonomic pan-cancer treatment strategies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Variations in the tumor microenvironment (TME) play crucial roles in tumor progression. Complex metabolic crosstalk, involving nutrient availability, physicochemical transformations, and intercellular interactions, between the immune system and TEM, directly or indirectly contribute to tumor immune escape. Over the recent decades, immune-based interventions, such as cellular antigenic epitope detection for tumor diagnosis, exogenous immune effectors for tumor therapy, and immunogenic tumor vaccine for tumor prevention, have shown great potential in clinical applications. However, the lack of a comprehensive understanding of the TME as it relates to immune treatment strategies administration could bring about unobjective effects on patients; for example, off-target effects, cytokine release syndrome, or organic adverse events. A further understanding of immunometabolic interplay mechanisms will facilitate tumor treatment, which is still of limited knowledge. Thus, explorations on immunometabolic interplay and TEM turbulence, from bench to bedside, will help clinicians have a better grasp on human disease treatment.
The issue of “metabonomics and cancer immunotherapy: interplay and clinical implications” aims at improving our understanding of immuno-metabolic variations in TME and assisting optimized strategy formulation in clinical practice. It will also thoroughly describe the interplay between metabolic networks, the body’s immunity, and TME. Based on advances in our understanding of the mechanism of immuno-metabolism, strategies for pan-cancer diagnosis, therapy, and prevention can be better investigated, which will improve solutions to current pan-cancer research impediments.
We welcome original research, review, mini-review, systematic review, and perspective articles on subtopics including, but not limited to:
1. Immunometabolic pan-cancer interplay.
2. Metabonomic analysis of tumor microenvironments
3. Metabonomic-related mechanisms for immune cell function and dysfunction, and tumor microenvironment turbulence
4. Optimized organoid models for tumor therapeutic research
5. Interdisciplinary studies on immunometabolic interplay
6. Immuno-metabonomic variations and their clinical pan-cancer implications
7. Immuno-metabolism targeted strategies for pan-cancer diagnosis, therapy, and prevention
8. Obstacles and solutions in immune-metabonomic pan-cancer treatment strategies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
